<aside> <img src="https://s3-us-west-2.amazonaws.com/secure.notion-static.com/9df46d1e-aef7-495c-b918-5fc15bd4ba6e/Icon_Blue.svg" alt="https://s3-us-west-2.amazonaws.com/secure.notion-static.com/9df46d1e-aef7-495c-b918-5fc15bd4ba6e/Icon_Blue.svg" width="40px" /> Welcome to Molecule! Here's everything you need to write about us. Should you have any additional questions just email [email protected]. You'll reach a real human who can arrange interviews and provide any additional material.
</aside>
Molecule is a decentralised biotech protocol. We're building a marketplace moving early-stage IP into web3 via NFTs coupled with frameworks to build biotech DAOs, communities consisting of patients, researchers, and enthusiasts coming together to fund research in specific therapeutic areas.
We currently have +300 projects listed on our platform, transacted first IP-NFTs with leading universities and helped launch VitaDAO.com a first biotech DAO funding longevity research with +$10m in funds raised and a community of 100s of researchers and over 3000 community members. In Q3 2021, our protocol generated +$5m in on-chain value and we recently closed a $11.5m Seed Round. Now we Scale. The Future of Medicine Belongs to Everyone.
When designing materials to feature Molecule, please make use our colour palette to align with our brand.
Molecule Brand Colour Guide.png
Molecule was conceptualised in 2018 by Paul Kohlhaas and Tyler Golato. They were connected through a mutual friend in South Africa and began riffing on how they could disrupt drug development by creating novel incentives to share IP. Their backgrounds were a natural fit for what came next.
Researchers often spend about 40% or more of their time trying to secure funding to keep their research projects alive. Time spent trying to secure funding means less time in the lab running experiments. Promising therapeutics may never see the light of day due to the administrative overload of grant writing and lack of collaboration with potential stakeholders who are interested in these therapeutics. The result is a “Valley of Death” where many good biomedical ideas wither away and die. Promising early-stage biopharma projects are discontinued and the early stage development cycle essentially halted. Lack of visibility and connection to relevant investors, the legal complexity of IP deals or the difficulty determining the value of early-stage biopharma assets all contribute to this Valley of Death. More on that here.